Table 5

Pre-RIT and post-RIT PSA velocity and pain-control response in 17 patients with androgen-independent metastatic prostate cancer

Cohorta90Y dose (GBq/m2)Pre-RIT PSA (mo)bPre-RIT PSA velocitycPost-RIT PSA velocitycPain-control responsedPain-control response CR + PRd(wk)
1A0.37032.040.53NR0
1A0.37070.17−1.43CR1 + 4
1A0.37020.20−0.04CR2 + 0
2A0.555110.58−2.07PR0 + 6
2A0.55560.631.69NAeNA
2A0.55550.120.21NAeNA
3A0.740110.160.58NAeNA
3A0.740110.20−0.90CR5 + 0
3A0.74080.432.07CR5 + 0
3A0.74050.631.64NRNA
3A0.74070.51−0.18NRNA
1B0.18580.250.58PR0 + 2
1B0.18561.033.90NR0
1B0.18540.480.66CR4 + 1
2B0.37083.1714.00NAeNA
2B0.37063.0532.20NR0
2B0.37022.400.38NR0
  • a Bone involvement for cohort A, ≤10%; bone involvement for cohort B, >10% ≤25%.

  • b Number of months of PSA values from which pre-RIT PSA velocity was calculated.

  • c Velocity = slope of PSA versus time. Post-RIT PSA velocity is for 1 month after RIT.

  • d NR, no response; CR, complete response; PR, partial response; NA, not applicable.

  • e Did not complain of pain prior to RIT.